A low-cost antidepressant may offer new hope for people struggling with long COVID fatigue. In a randomized clinical trial involving 399 adults, fluvoxamine significantly reduced fatigue and improved quality of life compared with a placebo, making it one of the first medications to show meaningful benefits for this disabling condition.
from Latest Science News -- ScienceDaily https://ift.tt/kqw0Yy9
No comments:
Post a Comment